生物类似药-话题@MedSci

#生物类似药#

27篇内容 | 2403人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1275616, encodeId=d40712e5616ac, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=国产生物类似药利妥昔单抗获批上市, objectType=article, longId=161099, objectId=2fe916109976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fe916109976, replyNumber=0, likeNumber=83, createdTime=2019-02-27, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fe916109976, moduleTitle=国产生物类似药利妥昔单抗获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fe916109976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275615, encodeId=eb2812e561572, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑, objectType=article, longId=144371, objectId=70851443e128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70851443e128, replyNumber=0, likeNumber=85, createdTime=2018-07-15, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70851443e128, moduleTitle=关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70851443e128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275614, encodeId=572312e5614b8, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=Lancet Oncol:生物类似药的曲折前行—LILAC研究, objectType=article, longId=140851, objectId=525514085151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525514085151, replyNumber=0, likeNumber=68, createdTime=2018-06-16, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525514085151, moduleTitle=Lancet Oncol:生物类似药的曲折前行—LILAC研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525514085151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275613, encodeId=2a6e12e56132b, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=未来10年生物类似药将为美国医疗节省1500亿美元, objectType=article, longId=117684, objectId=c45d11e684e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c45d11e684e2, replyNumber=0, likeNumber=75, createdTime=2017-10-28, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c45d11e684e2, moduleTitle=未来10年生物类似药将为美国医疗节省1500亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c45d11e684e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275612, encodeId=cb7012e561229, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=勃林格殷格翰阿达木单抗生物类似药CYLTEZO(R)获CHMP正面意见, objectType=article, longId=113775, objectId=d781113e75b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d781113e75b8, replyNumber=0, likeNumber=73, createdTime=2017-09-24, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d781113e75b8, moduleTitle=勃林格殷格翰阿达木单抗生物类似药CYLTEZO(R)获CHMP正面意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d781113e75b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275611, encodeId=602d12e561155, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=勃林格殷格翰的修美乐生物类似药获FDA批准, objectType=article, longId=112593, objectId=1db4112593da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1db4112593da, replyNumber=0, likeNumber=62, createdTime=2017-09-13, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1db4112593da, moduleTitle=勃林格殷格翰的修美乐生物类似药获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1db4112593da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275610, encodeId=83a912e5610e7, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=生物类似药领域的里程碑：罗氏赫赛汀安维汀生物类似药获批, objectType=article, longId=105512, objectId=db2e10551207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db2e10551207, replyNumber=0, likeNumber=66, createdTime=2017-07-16, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db2e10551207, moduleTitle=生物类似药领域的里程碑：罗氏赫赛汀安维汀生物类似药获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db2e10551207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275609, encodeId=9bdc12e5609a6, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=野百合也有春 56个生物类似药绽放, objectType=article, longId=96456, objectId=36d896456d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36d896456d5, replyNumber=0, likeNumber=63, createdTime=2017-04-21, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36d896456d5, moduleTitle=野百合也有春 56个生物类似药绽放, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36d896456d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275608, encodeId=1fb012e5608d9, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, objectType=article, longId=77934, objectId=92cfe7934e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cfe7934e2, replyNumber=0, likeNumber=65, createdTime=2016-09-21, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cfe7934e2, moduleTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cfe7934e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275607, encodeId=853a12e5607e7, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=Enbrel生物类似药Erelzi获FDA批准上市, objectType=article, longId=76403, objectId=e523e640301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e523e640301, replyNumber=0, likeNumber=64, createdTime=2016-09-02, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e523e640301, moduleTitle=Enbrel生物类似药Erelzi获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e523e640301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275606, encodeId=97b312e560603, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=生物类似药全球三巨头是怎样炼成的？必备6种研发能力, objectType=article, longId=44242, objectId=5046442423f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5046442423f, replyNumber=0, likeNumber=71, createdTime=2014-12-20, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5046442423f, moduleTitle=生物类似药全球三巨头是怎样炼成的？必备6种研发能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5046442423f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1275605, encodeId=58d112e560594, content=<a href='/topic/show?id=53db6942572' target=_blank style='color:#2F92EE;'>#生物类似药#</a>, objectTitle=全球生物制剂拐点：重磅生物药如何应对生物类似药的竞争, objectType=article, longId=40987, objectId=458d4098e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=458d4098e7b, replyNumber=0, likeNumber=80, createdTime=2014-10-10, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=458d4098e7b, moduleTitle=全球生物制剂拐点：重磅生物药如何应对生物类似药的竞争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=458d4098e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生物类似药

2020-05-29

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

国产生物类似药利妥昔单抗获批上市

2019-02-27

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑

2018-07-15

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

Lancet Oncol:生物类似药的曲折前行—LILAC研究

2018-06-16

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

未来10年生物类似药将为美国医疗节省1500亿美元

2017-10-28

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

勃林格殷格翰阿达木单抗生物类似药CYLTEZO(R)获CHMP正面意见

2017-09-24

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

勃林格殷格翰的修美乐生物类似药获FDA批准

2017-09-13

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

生物类似药领域的里程碑：罗氏赫赛汀安维汀生物类似药获批

2017-07-16

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

野百合也有春 56个生物类似药绽放

2017-04-21

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功

2016-09-21

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

Enbrel生物类似药Erelzi获FDA批准上市

2016-09-02

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

生物类似药全球三巨头是怎样炼成的？必备6种研发能力

2014-12-20

yyj062 (审核中...)

前往app查看评论内容

#生物类似药#

全球生物制剂拐点：重磅生物药如何应对生物类似药的竞争

2014-10-10

科室
- - 订阅+
  - 更多科室
工具
服务